Literature DB >> 2940298

Natural cytotoxic (NC) cell activity in basophilic cells: release of NC-specific cytotoxic factor by IgE receptor triggering.

T Okuno, Y Takagaki, D H Pluznik, J Y Djeu.   

Abstract

A murine interleukin 3 (IL 3)-dependent basophilic mast cell line, PT-18 (A17), and a rat basophilic leukemic cell line, RBL-2H3, were shown to be capable of selective natural cytotoxic (NC) but not natural killer (NK) cell activity. The basophilic cell types could also be augmented in their NC activity by bridging of their surface IgE receptors. IgE-mediated triggering of the basophilic cells was accomplished by coating the cells with IgE and exposing the IgE-bound cells to specific antigen or to anti-IgE monoclonal antibody. Another method of triggering was by direct binding of basophilic cells to anti-IgE receptor monoclonal antibody. Basophilic cells, triggered by these methods, not only displayed increased NC activity but also released a soluble factor capable of selectively lysing NC tumor targets, WEHI-164, but not three of the NK-sensitive targets, YAC-1, RLM1, and RBL-5. Normal C3H/HeJ mouse embryonic fibroblasts were also not lysed. Dose response and time course of the cytotoxic factor release from triggered RBL-2H3 cells were similar to those of tritiated serotonin release. As with serotonin or histamine release, the NC-specific cytotoxic factor (NCCF) was not released in the absence of extracellular calcium. Therefore, NCCF appears to be released along with other mediators during the triggering of basophilic cells by bridging of IgE receptors. The m.w. of the native form of this factor, determined by a gel filtration method, was about 43,000.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940298

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  IgE and immune defense mechanism.

Authors:  J P Dessaint; A Capron
Journal:  Clin Rev Allergy       Date:  1989

Review 2.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Authors:  M P Bernard; S Bancos; P J Sime; R P Phipps
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 4.  Fc epsilon receptor II-positive macrophages and platelets: potent effector cells in allergy and defence against helminth parasites.

Authors:  J P Dessaint; A Capron
Journal:  Springer Semin Immunopathol       Date:  1990

Review 5.  Mast cells as sources of cytokines, chemokines, and growth factors.

Authors:  Kaori Mukai; Mindy Tsai; Hirohisa Saito; Stephen J Galli
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

6.  Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion.

Authors:  L M Klein; R M Lavker; W L Matis; G F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Identification, purification, and characterization of a mast cell-associated cytolytic factor related to tumor necrosis factor.

Authors:  J D Young; C C Liu; G Butler; Z A Cohn; S J Galli
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

8.  Presence of tumour necrosis factor or a related factor in human basophil/mast cells.

Authors:  M Steffen; M Abboud; G K Potter; Y P Yung; M A Moore
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

9.  Sequential mast cell infiltration and degranulation during experimental carcinogenesis.

Authors:  E A Flynn; J L Schwartz; G Shklar
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Characterization of target injury of murine acute graft-versus-host disease directed to multiple minor histocompatibility antigens elicited by either CD4+ or CD8+ effector cells.

Authors:  G F Murphy; D Whitaker; J Sprent; R Korngold
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.